• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TEOXANE RHA2; RESILIENT HYALURONIC ACID

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TEOXANE RHA2; RESILIENT HYALURONIC ACID Back to Search Results
Device Problem Off-Label Use (1494)
Patient Problem Obstruction/Occlusion (2422)
Event Date 08/11/2022
Event Type  Injury  
Event Description
Vascular occlusion or very bad bruise [vascular occlusion], rha2 in the lip or around the mouth [off label use].United states report received from a healthcare professional on (b)(6) 2022.A nurse who was also the injector reported that a female patient of an unknown age had received rha2 product for unknown indication, in (b)(6) 2022.An unknown volume of rha2 injection was applied to the lips or around the mouth (as mentioned not sure of the injection site) using an unknown injection technique.It was unknown if the needle was used from the box and cannula was used for the administration of the rha2 product.No previous cosmetic procedures were done.Medical history was not provided.Concomitant medications, and food supplements were not provided.It was unknown if any concomitant fillers and previous facial fillers were used.On 11-aug-2022, after an unspecified time, the patient experienced vascular occlusion or very bad bruise.As a treatment, the prescriber applied heat, massage and was dissolved now.The outcome of the event was not reported.The product was not available for return.The intensity of the event was not reported.(b)(4).No additional information was available at the time of this report.Case comment: a causal relationship between the rha2 and reported vascular occlusion is assessed as possible based on the compatible temporal relationship and the lack of alternative etiologies that can be identified based on the limited information reported.The company will continue monitoring the benefit-risk profile for the product.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RHA2
Type of Device
RESILIENT HYALURONIC ACID
Manufacturer (Section D)
TEOXANE
les charmilles
rue de lyon, 105
geneva, ch 1203
SZ  1203
MDR Report Key15364296
MDR Text Key299357289
Report Number3007772056-2022-00018
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Nurse Practitioner
Type of Report Initial
Report Date 09/06/2022,08/11/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/06/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? Yes
Date Report Sent to FDA09/06/2022
Distributor Facility Aware Date08/11/2022
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
Patient SexFemale
-
-